Bringing the number of Synexus’ Dedicated Research Centres to seventeen is its recently completed purchase of CLCC which has centers in the major conurbations of Warsaw, Gdynia and Katowice. These centers will work closely with Synexus’ Polish clinical trial centre in Wroclaw.
Michael Fort, Chief Executive of Synexus commented “This acquisition provides us with access to millions more patients and a wider range of therapy areas. The Synexus model continues to gain ground with our clients in pharma who recognize the benefits that the streamlined recruitment processes the Dedicated Research Centres deliver, namely helping to speed up trials, reduce costs and drive up quality. We are actively looking for further acquisitions, and in particular to increase our presence in India. These new centers will ensure that our growth in 2008 will be repeated in 2009."
Dr Andrzej Opadczuk, who previously owned CLCC, will continue to manage the centres and will report to Synexus CEE Vice President, Dr Christian Tueni. The management of the new centers will be trained in the Synexus Quality Assurance System and will follow the worldwide SOPs which ensure that all Synexus Dedicated Research Centres offer the same high level of good clinical practice and patient care. The centers will change their name to Synexus immediately.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.